Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 2
1998 1
2001 2
2002 3
2003 5
2004 6
2008 3
2009 4
2010 8
2011 4
2012 7
2013 5
2014 11
2015 10
2016 13
2017 5
2018 10
2019 15
2020 11
Text availability
Article attribute
Article type
Publication date

Search Results

113 results
Results by year
Filters applied: . Clear all
Page 1
The clinical symptoms of Parkinson's disease.
Sveinbjornsdottir S. Sveinbjornsdottir S. J Neurochem. 2016 Oct;139 Suppl 1:318-324. doi: 10.1111/jnc.13691. Epub 2016 Jul 11. J Neurochem. 2016. PMID: 27401947 Free article. Review.
Review of the Clinical Evidences of Modulated Electro-Hyperthermia (mEHT) Method: An Update for the Practicing Oncologist.
Szasz AM, Minnaar CA, Szentmártoni G, Szigeti GP, Dank M. Szasz AM, et al. Front Oncol. 2019 Nov 1;9:1012. doi: 10.3389/fonc.2019.01012. eCollection 2019. Front Oncol. 2019. PMID: 31737558 Free PMC article. Review.
Aim: In this paper we review the literature on the effects of mEHT in cancer patients on local disease control and survival. ...Conclusion: Based on clinical studies, the method mEHT is a feasible hyperthermia technology for oncological applications. Concomitant uti …
Aim: In this paper we review the literature on the effects of mEHT in cancer patients on local disease control and survival. ...Concl …
Modulated Electro-Hyperthermia as Palliative Treatment for Pancreatic Cancer: A Retrospective Observational Study on 106 Patients.
Fiorentini G, Sarti D, Casadei V, Milandri C, Dentico P, Mambrini A, Nani R, Fiorentini C, Guadagni S. Fiorentini G, et al. Integr Cancer Ther. 2019 Jan-Dec;18:1534735419878505. doi: 10.1177/1534735419878505. Integr Cancer Ther. 2019. PMID: 31561722 Free PMC article. Clinical Trial.
They were divided into 2 groups: patients who did not receive mEHT (no-mEHT) and patients who were treated with mEHT. We performed mEHT applying a power of 60 to 150 W for 40 to 90 minutes. The mEHT treatment was associated with chemotherapy and …
They were divided into 2 groups: patients who did not receive mEHT (no-mEHT) and patients who were treated with mEHT. W …
Combined treatment with modulated electro-hyperthermia and an autophagy inhibitor effectively inhibit ovarian and cervical cancer growth.
Yang W, Han GH, Shin HY, Lee EJ, Cho H, Chay DB, Kim JH. Yang W, et al. Int J Hyperthermia. 2019;36(1):9-20. doi: 10.1080/02656736.2018.1528390. Epub 2018 Nov 14. Int J Hyperthermia. 2019. PMID: 30428738
We determined that mEHT-induced cellular damage recovery was mediated by autophagy and, therefore, expectedly, cotreatment with mEHT and 3-methyladenine (3-MA), an autophagy inhibitor, more effectively inhibited cancer cell growth than individual treatment did. CONC …
We determined that mEHT-induced cellular damage recovery was mediated by autophagy and, therefore, expectedly, cotreatment with mE …
Modulated electro-hyperthermia induced p53 driven apoptosis and cell cycle arrest additively support doxorubicin chemotherapy of colorectal cancer in vitro.
Vancsik T, Forika G, Balogh A, Kiss E, Krenacs T. Vancsik T, et al. Cancer Med. 2019 Aug;8(9):4292-4303. doi: 10.1002/cam4.2330. Epub 2019 Jun 10. Cancer Med. 2019. PMID: 31183995 Free PMC article.
Here we tested the molecular background of mEHT and its combination with doxorubicin chemotherapy using an in vitro model. METHODS: C26 mouse colorectal adenocarcinoma cultures were mEHT treated at 42°C for 2 × 60 minutes (with 120 minutes interruption) either alone …
Here we tested the molecular background of mEHT and its combination with doxorubicin chemotherapy using an in vitro model. METHODS: C …
Phase I/II clinical trial of modulated electro-hyperthermia treatment in patients with relapsed, refractory or progressive heavily treated ovarian cancer.
Yoo HJ, Lim MC, Seo SS, Kang S, Joo J, Park SY. Yoo HJ, et al. Jpn J Clin Oncol. 2019 Sep 1;49(9):832-838. doi: 10.1093/jjco/hyz071. Jpn J Clin Oncol. 2019. PMID: 31070763 Clinical Trial.
OBJECTIVE: To determine the maximal tolerated dose (MTD) of modulated electro-hyperthermia (mEHT) treatment and to reveal whether mEHT treatment is feasible and effective as second-line therapy in recurrent and progressive ovarian cancer. ...CONCLUSIONS: The mEHT …
OBJECTIVE: To determine the maximal tolerated dose (MTD) of modulated electro-hyperthermia (mEHT) treatment and to reveal whether …
Stress-Induced, p53-Mediated Tumor Growth Inhibition of Melanoma by Modulated Electrohyperthermia in Mouse Models without Major Immunogenic Effects.
Besztercei B, Vancsik T, Benedek A, Major E, Thomas MJ, Schvarcz CA, Krenács T, Benyó Z, Balogh A. Besztercei B, et al. Int J Mol Sci. 2019 Aug 17;20(16):4019. doi: 10.3390/ijms20164019. Int J Mol Sci. 2019. PMID: 31426515 Free PMC article.
Here, we tested the efficiency of high-fever range (~42 °C) mEHT on B16F10 melanoma both in cell culture and allograft models. ...Combined in vitro treatment with mEHT and the p53 activator nutlin-3a additively reduced cell viability compared to monotherapies. ...
Here, we tested the efficiency of high-fever range (~42 °C) mEHT on B16F10 melanoma both in cell culture and allograft models. ...Com …
The safety and pharmacokinetics of high dose intravenous ascorbic acid synergy with modulated electrohyperthermia in Chinese patients with stage III-IV non-small cell lung cancer.
Ou J, Zhu X, Lu Y, Zhao C, Zhang H, Wang X, Gui X, Wang J, Zhang X, Zhang T, Pang CLK. Ou J, et al. Eur J Pharm Sci. 2017 Nov 15;109:412-418. doi: 10.1016/j.ejps.2017.08.011. Epub 2017 Aug 25. Eur J Pharm Sci. 2017. PMID: 28847527 Clinical Trial.
Ascorbic acid (AA) infusion and modulated electrohyperthermia (mEHT) are widely used by integrative cancer practitioners for many years. ...Participants in the first group received intravenous AA (IVAA) when mEHT was finished, in the second group IVAA was administer …
Ascorbic acid (AA) infusion and modulated electrohyperthermia (mEHT) are widely used by integrative cancer practitioners for many yea …
[Mechanism of action of modulated electro- hyperthermia (mEHT) induced tumor damage in colorectal adenocarcinoma models].
Krenács T, Meggyesházi N, Kõvágó C, Kiss É, Forika G, Balogh A, Vancsik T. Krenács T, et al. Magy Onkol. 2019 Dec 9;63(4):359-364. Epub 2019 Nov 14. Magy Onkol. 2019. PMID: 31821391 Free article. Hungarian.
Modulated electro-hyperthermia (mEHT) is a non-invasive treatment modality of cancer where electric field generated by 13.56 MHz radiofrequency can selectively accumulate in malignant tumors compared to adjacent normal tissues. ...We earlier showed that mEHT has its …
Modulated electro-hyperthermia (mEHT) is a non-invasive treatment modality of cancer where electric field generated by 13.56 MHz radi …
Modulated Electrohyperthermia in Integrative Cancer Treatment for Relapsed Malignant Glioblastoma and Astrocytoma: Retrospective Multicenter Controlled Study.
Fiorentini G, Sarti D, Milandri C, Dentico P, Mambrini A, Fiorentini C, Mattioli G, Casadei V, Guadagni S. Fiorentini G, et al. Integr Cancer Ther. 2019 Jan-Dec;18:1534735418812691. doi: 10.1177/1534735418812691. Epub 2018 Dec 22. Integr Cancer Ther. 2019. PMID: 30580645 Free PMC article. Clinical Trial.
The 5-year overall survival of AST was 83% after mEHT versus 25% after BSC and 3.5% after mEHT versus 1.2% after BSC for GBM. ...Two of the long survivors in AST and 1 in GBM group were treated by mEHT. CONCLUSIONS: mEHT in integrative therapy may have …
The 5-year overall survival of AST was 83% after mEHT versus 25% after BSC and 3.5% after mEHT versus 1.2% after BSC for GBM. …
113 results
Jump to page
Feedback